56468-24-7

Upstream product

• 1040751-47-0 N-((3-chloropyrazin-2-yl)methyl)acetamide 
• 771581-15-8 (3-chloro-pyrazin-2-yl)-methylamine 
• 55557-52-3 2-chloro-3-cyanopyrazine 
• 56468-23-6 8-chloro-imidazo[1,5-a]pyrazine 
• 74-88-4 methyl iodide 

Downstream Products

• 1040751-82-3 C₁₃H₁₀FN₃ 
• 1040751-81-2 C₁₄H₁₃N₃O 
• 1040751-83-4 C₁₃H₁₀N₄O₂ 
• 1040751-84-5 C₁₃H₁₀N₄O₂ 
• 1040751-50-5 8-amino-3-methylimidazo[1,5-a]pyrazine 
• 1195989-74-2 C₁₇H₁₈ClN₃O 
• 1195989-72-0 C₁₄H₁₁ClN₄O₃ 
• 1195989-73-1 C₁₅H₁₄ClN₃O₂ 
• 1195989-64-0 C₈H₈ClN₃ 
• 1083164-36-6 8-amino-N-(4-((((3-fluorophenyl)amino)carbonyl)amino)phenyl)-3-methylimidazo[1,5-a]pyrazine-1-carboxamide 

Relevant academic research and scientific papers

NOVEL COMPOUNDS

The present disclosure relates to novel PDE2 inhibitory compounds of Formula I as described herein, their use as pharmaceuticals and pharmaceutical compositions comprising them.

HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF

Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated modulate the NMDA receptor.

FUSED HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS

Fused heteroaryl derivative compounds which are antagonists of orexin receptors are provided. The compounds can be used in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. Also provided is a composition which comprises the compound can be use to prevent or treat such diseases in which orexin receptors are involved.

4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors

The present invention provides 6-5 membered fused pyridine ring compounds according to Formula I or pharmaceutically acceptable salts thereof. or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.

Synthesis of substituted imidazo[1,5-a]pyrazines via Mono-, Di-, and directed remote metalation strategies

Imidazo[1,5-a]pyrazines 1 undergo regioselective C3-metalation and C5/C3-dimetalation to afford a range of functionalized derivatives 2a-2g (Table 1), and 4a-4d (Table 2). Under similar conditions, the C3-methyl derivatives 2a and 5 undergo surprising reg

CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PROTEIN KINASES

Compounds having Formula (I) that inhibit Aurora-kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.

Palladium-catalyzed direct Heck arylation of dual π-deficient/π- excessive heteroaromatics. Synthesis of C-5 arylated imidazo[1,5-a]pyrazines

(Chemical Equation Presented) A general and efficient synthesis of 5-aryl imidazo[1,5-a]pyrazines by palladium-catalyzed coupling of the corresponding 8-substituted derivatives with aryl halides is described. The scope of this new reaction for the imidazo[1,5-a]pyrazine ring system was explored using three readily available 8-substituted precursors, X = NH2, NMe2, and OMe, as well as 8-aryl derivatives, X = Ar?. On the basis of these results as well as studies using a deuterated derivative, a Heck-like mechanism is proposed for this transformation.

CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PROTEIN KINASES

Compounds having Formula (I) that inhibit Aurora-kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.